Abstracts tagged "Adalimumab"

Abstract Number: 45 • 2017 Pediatric Rheumatology Symposium
Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn’s Disease
Gerd Horneff¹, Marieke M. B. Seyger², Dilek Arikan³, Jasmina Kalabic⁴, Jaclyn K. Anderson³, Andreas Lazar⁵, David A. Williams³, Chen Wang³, Rita Tarzynski-Potempa³ and Jeffrey S. Hyams⁶, ¹Asklepios Clinic, Sankt Augustin, Germany, ²Radboud University Nijmegen Medical Center, Nijmegen, Netherlands, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Deutschland GmbH & Co. KG, North ChicagoLudwigshafen, IL, Germany, ⁶Connecticut Children’s Medical Center, Hartford, CT
Background/Purpose: Adalimumab (ADA) is a tumor necrosis factor (TNF) inhibitor used for treatment of chronic immune diseases. The safety of ADA treatment in pediatric patients…
Abstract Number: 11 • 2017 Pediatric Rheumatology Symposium
Safety of Adalimumab ± Methotrexate for the Treatment of Polyarticular Juvenile Idiopathic Arthritis (pJIA): STRIVE Registry
Hermine Brunner¹, Nicolino Ruperto², Kabita Nanda³, Mary Toth⁴, Ivan Foeldvari⁵, John F. Bohnsack⁶, Diana Milojevic⁷, C. Egla Rabinovich⁸, Daniel Kingsbury⁹, Katherine Marzan¹⁰, Pierre Quartier¹¹, Kirsten Minden¹², Elizabeth Chalom¹³, Gerd Horneff¹⁴, Rolf M. Kuester¹⁵, Jason A Dare¹⁶, Mareike Bereswill¹⁷, Jasmina Kalabic¹⁷, Hartmut Kupper¹⁸, Daniel J. Lovell¹⁹ and Alberto Martini², ¹Rheumatology, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²PRINTO-IRCCS Gaslini, Genova, Italy, ³Seattle Childrens Hospital, Bayside, NY, ⁴Rheumatology, Akron Children's Hospital, Akron, OH, ⁵Kinder- und Jugenrheumatologie, Hamburger Zentrum Kinder-und Jugendrheumatologie, Hamburg, Germany, ⁶Division of Allergy, Immunology and Pediatric Rheumatology, University of Utah, Salt Lake City, UT, ⁷Tufts Medical Center, Boston, MA, ⁸Duke University Medical Center, Durham, NJ, ⁹Pediatric Rheumatology, Randall Children's Hospital at Legacy Emanuel, Portland, OR, ¹⁰Children's Hospital Los Angeles, Los Angeles, CA, ¹¹Hopital Necker-Enfants Malades, Paris, France, ¹²Kinderklinik der Charite, Otto-Heubner Centrum, Berlin, Germany, ¹³PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁴Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ¹⁵Orthopädiezentrum Altona, Hamburg, Germany, ¹⁶Arkansas Children’s Hospital, Little Rock, AR, ¹⁷AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ¹⁸Clinical Oncology/Immunology, AbbVie Deutschland GmbH & Co. KG, Ludnigshafen, Germany, ¹⁹Rheumatology MLC 4010, PRCSG, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: JIA is the most common chronic inflammatory rheumatic disease of childhood. Due to their known safety and efficacy, TNF inhibitors are used for long-term…
Abstract Number: 46 • 2017 Pediatric Rheumatology Symposium
Long-term Efficacy and Safety of Adalimumab in Pediatric Patients with Enthesitis Related Arthritis
Rubén Burgos-Vargas¹, Shirley M.L. Tse², Gerd Horneff³, Kristina Unnebrink⁴ and Jaclyn K. Anderson⁵, ¹Hospital General de Mexico, Universidad Nacional Autonoma de Mexico, Mexico City, Mexico, ²University of Toronto, The Hospital for Sick Children, Toronto, ON, Canada, ³Asklepios Klinik Sankt Augustin, Sankt Augustin, Germany, ⁴AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, ⁵AbbVie Inc., North Chicago, IL
Background/Purpose: Enthesitis-related arthritis (ERA) is a JIA category primarily affecting entheses and peripheral joints but can involve the axial skeleton. Disease activity and structural change…
Abstract Number: 62 • 2016 ACR/ARHP Annual Meeting
Increased Frequency of Anti-Drug Antibodies in Patients Carrying Compatible IgG1 Allotypes and Treated with Anti-TNF Antibodies
Antonio Gonzalez¹, Rosario Lopez-Rodriguez¹, Ana Martinez², Chamaida Plasencia-Rodriguez², Andrea Jochems², Dora Pascual-Salcedo² and Alejandro Balsa², ¹Instituto Investigacion Sanitaria-Hospital Clinico Universitario de Santiago, Santiago de Compostela, Spain, ²Instituto de Investigación Hospital Universitario La Paz (IDIPAZ), Madrid, Spain
Background/Purpose: One of the causes of insufficient response to biological drugs is the production of anti-drug antibodies (ADA) (1). These antibodies can decrease the effectiveness…
Abstract Number: 641 • 2016 ACR/ARHP Annual Meeting
Reduction of Concomitant Oral Methotrexate or Corticosteroids in Combination Treatment with Adalimumab Does Not Affect Effectiveness in Patients with Rheumatoid Arthritis
Edward Keystone¹, Ferdinand Breedveld², Arthur Kavanaugh³, Ying Zhang⁴, Iain Sainsbury⁴ and Jasmina Kalabic⁵, ¹Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Leiden University Medical Center, Leiden, Netherlands, ³Univ of California San Diego, San Diego, CA, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: In rheumatoid arthritis (RA) patients (pts) receiving corticosteroids (CS) or methotrexate (MTX) with an anti-TNF, such as adalimumab (ADA), the concomitant CS or MTX…
Abstract Number: 2504 • 2016 ACR/ARHP Annual Meeting
Impaired Vasodilator Function in Rheumatoid Arthritis Patients Who Flared Due to Stopping Adalimumab or Etanercept
Gerard A Rongen¹, Iris van Ingen² and Tim L Jansen^3,4, ¹Internal Medicine/Pharmacology and Toxicology, Radboud UMC, Nijmegen, Netherlands, ²Rheumatology, RadboudUMC, Nijmegen, Netherlands, ³Rheumatology, VieCuri Medical Centre, Venlo, Netherlands, ⁴Scientific IQ HealthCare, Radboud UMC, Nijmegen, Netherlands
Background/Purpose: Chronic inflammation in rheumatoid arthritis (RA) is associated with an increased cardiovascular risk, possibly due to disrupted vascular vasodilation. Within 12 weeks adalimumab and…
Abstract Number: 63 • 2016 ACR/ARHP Annual Meeting
Identification of Immune Gene Modules in Good Responders to Adalimumab in Rheumatoid Arthritis
James OIiver¹, Darren Plant², Gisela Orozco¹, Samantha Smith¹, Kimme L. Hyrich³, Ann Morgan⁴, John Isaacs⁵, Anthony G. Wilson⁶ and Anne Barton^1,2, ¹Arthritis Research UK, Centre for Genetics and Genomics, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal BRU, Central Manchester Foundation Trust, Manchester, United Kingdom, ³Arthritis Research UK, Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Sciences Centre, The University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, Great Britain, ⁵Institute of Cellular Medicine, Newcastle University and National Institute for Health Research Newcastle Biomedical Research Centre at Newcastle upon Tyne Hospitals NHS Foundation Trust and Newcastle University, Newcastle, United Kingdom, ⁶UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Dublin, Ireland
Background/Purpose: Despite the revolutionary impact of TNF inhibitor (TNFi) therapy in rheumatoid arthritis (RA), up to 40% of patients fail to respond adequately. Whilst non-responder…
Abstract Number: 698 • 2016 ACR/ARHP Annual Meeting
Performance of Modified Minimal Disease Activity (MDA) in Patients with Peripheral Spondyloarthritis
Laura C. Coates¹, Sonya Abraham², William Tillett³, Philip J Mease⁴, Sofia Ramiro⁵, Yinglin Xia⁶, Xin Wang⁷, Aileen L. Pangan⁷ and In-Ho Song⁷, ¹University of Leeds, Leeds, United Kingdom, ²NIHR/Wellcome CRF, Imperial College Healthcare NHS Trust, London, United Kingdom, ³Rheumatology, Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁴Swedish Medical Center and University of Washington, Seattle, WA, ⁵Leiden University Medical Center, Leiden, Netherlands, ⁶University of Illinois at Chicago, Chicago, IL, ⁷AbbVie Inc., North Chicago, IL
Background/Purpose: Due to lack of validated outcome measures in non-psoriatic peripheral spondyloarthritis (pSpA), recent studies in this patient (pt) population have used varying endpoints [1].…
Abstract Number: 2526 • 2016 ACR/ARHP Annual Meeting
TNF Blocker Concentrations or Detection of Antibodies Against Anti-TNF before a Tapering Process Are Not Predictive to Relapse
Hubert Marotte^1,2, Mélanie Rinaudo-Gaujous³, Stéphane Paul^3,4 and Bruno Fautrel⁵, ¹SAINBIOSE INSERM U1059 and Rheumatology department, University of Lyon and University Hospital of Saint Etienne, Saint Etienne, France, ²Rheumatology Department, University Hospital of Saint-Etienne, Saint-Etienne, France, ³Laboratory of Immunology and immunomonitoring, CIC CIE3 Inserm Vaccinology, GIMAP EA3064, Hôpital Nord, Saint-Etienne, France, ⁴Centre Hospitalier Universitaire de Saint-Étienne, Saint-Étienne, France, ⁵Rheumatology, Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: The goal of rheumatoid arthritis (RA) strategy is to reach remission or at least a low disease activity. When this goal is reached, no…
Abstract Number: 80 • 2016 ACR/ARHP Annual Meeting
Impact of a Patient Support Program on Abandonment of Adalimumab Treatment Initiation in Patients with Rheumatoid Arthritis, Ankylosing Spondylitis, and Psoriatic Arthritis
Philip Mease¹, Manish Mittal², Martha Skup², Matthew Davis³, Arijit Ganguli², Scott Johnson³ and Michael Schiff⁴, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²AbbVie Inc., North Chicago, IL, ³Medicus Economics, LLC, Milton, MA, ⁴University of Colorado, Greenwood Village, CO
Background/Purpose: Treatment abandonment (failure to start therapy after prescription) is common among patients (pts) prescribed specialty pharmaceuticals. AbbVie offers a pt support program (PSP) for…
Abstract Number: 700 • 2016 ACR/ARHP Annual Meeting
Incidence of Inflammatory Bowel Disease Events in Adalimumab (HUMIRA) Clinical Trials Across Indications
Jeffrey R. Curtis¹, Dirk Elewaut², Su Chen³, Maja Hojnik⁴, Navit Naveh⁵ and Jaclyn K. Anderson³, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²VIB Inflammation Research Center, University of Ghent, Ghent, Belgium, ³AbbVie Inc., North Chicago, IL, ⁴AbbVie, Ljubljana, Slovenia, ⁵AbbVie, Hod HaSharon, Israel
Background/Purpose: Adalimumab (ADA) is approved for treatment of Crohn’s disease (CD) and ulcerative colitis (UC); therefore, it is postulated that new onset or flare of…
Abstract Number: 2531 • 2016 ACR/ARHP Annual Meeting
Impact of Participation in the Adalimumab (Humira) Patient Support Program on Functional and Clinical Outcomes Among Patients with Rheumatoid Arthritis: Passion Study
Filip van Den Bosch¹, Andrew Östör², Siegfried Wassenberg³, Jaclyn K. Anderson⁴, Naijun Chen⁵, Chen Wang⁴, Vishvas Garg⁵ and Jasmina Kalabic⁶, ¹Rheumatology, Ghent University Hospital, Gent, Belgium, ²Addenbrooke's Hospital, Cambridge, United Kingdom, ³Rheumazentrum, Ratingen, Germany, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc, North Chicago, IL, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Patients (pt) with Rheumatoid arthritis (RA) who are treated with adalimumab (ADA) are offered a Patient Support Program (PSP) with variety of services. To…
Abstract Number: 84 • 2016 ACR/ARHP Annual Meeting
Treatment Outcomes and Predictors of Patient Support Program Use Among Patients with Rheumatoid Arthritis: Results from a Post-Marketing Observational Study (PMOS)
Filip van Den Bosch¹, Siegfried Wassenberg², Andrew Östör³, Chen Wang⁴, Jasmina Kalabic⁵ and Vishvas Garg⁴, ¹Rheumatology, Ghent University Hospital, Gent, Belgium, ²Rheumazentrum, Ratingen, Germany, ³Addenbrooke's Hospital, Cambridge, United Kingdom, ⁴AbbVie Inc, North Chicago, IL, ⁵AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany
Background/Purpose: Patient (pt) support programs (PSPs) are offered to Rheumatoid arthritis (RA) pts to help manage treatment of this chronic disease. Little information is available…
Abstract Number: 701 • 2016 ACR/ARHP Annual Meeting
In Patients with Ankylosing Spondylitis Treated with Adalimumab, Combination Therapy with DMARD, Increase the Serum Level of Adalimumab and Decrease Immunogenicity
José Rosas¹, Francisca Llinares-Tello², José Miguel Senabre-Gallego¹, Mariana Marco-Mingot³, Ana Pons¹, Xavier Barber⁴, Gregorio Santos-Soler¹, Esteban Salas-Heredia¹, Catalina Cano¹, Juan Molina³, Marina Sanchís⁴, Mario García-Carrasco⁵ and AIRE-MB Group, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ³Laboratory, Hospital Marina Baixa, Villajoyosa (Alicante), Spain, ⁴CIO, Universidad Miguel Hernández, Elche, Spain, ⁵Systemic Autoimmune Diseases Research Unit, HGR 36-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico
Background/Purpose: In patients with rheumatoid arthritis, methotrexate (MTX), improves the clinical efficacy of anti-TNF (TNFi), among other reasons, for reducing the immunogenicity. However, there are…
Abstract Number: 2601 • 2016 ACR/ARHP Annual Meeting
A Cytometric Assay for Monitoring Adalimumab Immunogenicity and Drug Concentrations Can Distinguish Anti-Adalimumab Antibodies from Interference
Morgan Casal¹, Manda Ramsey¹, Larry W. Moreland² and Christian Fernandez¹, ¹Center for Pharmacogenetics and Department of Pharmaceutical Sciences, University of Pittsburgh, Pittsburgh, PA, ²Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Tumor necrosis factor inhibitor (TNFi) biologics are a mainstay of therapy for rheumatoid arthritis (RA) patients with disease-modifying antirheumatic drug failure. However, RA patients…

« Previous Page
1
…
4
5
6
7
8
…
17
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].